Drug Interactions with Antihypertensive Medications in Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Concurrent administration of ACE inhibitors and NSAIDs significantly increases the risk of reduced renal perfusion and hyperkalemia due to synergistic inhibition of renal prostaglandins and aldosterone. This combination necessitates close monitoring of serum creatinine and potassium within 7 days of initiation or dose adjustment, particularly in volume-depleted or renally compromised patients.
• Beta-blockers combined with epinephrine or other alpha-beta agonists can lead to severe, paradoxical hypertension due to unopposed alpha-adrenergic vasoconstriction; this combination should be avoided, especially in anesthetic emergencies or when local anesthetics with epinephrine are used.
• Antihypertensive medications, particularly ACE inhibitors and ARBs, can potentiate anesthetic-induced hypotension by blunting compensatory renin-angiotensin responses; anesthetic inhalant concentrations should be reduced, and direct blood pressure monitoring is critical.
• Enzyme-inducing antiseizure medications, such as phenobarbital, can reduce plasma concentrations of calcium channel blockers (e.g., amlodipine) through hepatic cytochrome P450 induction, potentially requiring dose escalation of the antihypertensive with therapeutic drug monitoring or close blood pressure assessment.
• Corticosteroids promote sodium and water retention, directly opposing the natriuretic effects of ACE inhibitors and diuretics, often leading to apparent antihypertensive failure; blood pressure reassessment within 2 weeks of corticosteroid initiation or discontinuation is crucial.
• The veterinary evidence base for antihypertensive drug interactions is often extrapolated from human medicine, necessitating cautious interpretation and explicit identification of knowledge gaps regarding species-specific clinical consequences and optimal management strategies.

Systemic hypertension in dogs and cats is managed with a limited pharmacologic armamentarium: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, and diuretics. Each class operates within overlapping physiologic pathways, which creates predictable interaction surfaces with common veterinary drugs. This article examines those interactions for the practicing veterinarian, focusing on NSAIDs, corticosteroids, anesthetics, and other cardiovascular agents. It also addresses interactions with immunosuppressants, antiseizure medications, and drugs used in managing comorbid endocrine disease. The clinical question answered here is practical: when a hypertensive patient requires additional medication, which combinations demand dose adjustment, enhanced monitoring, or avoidance?

The evidence base for veterinary antihypertensive drug interactions is uneven. Some interactions are well characterized in dogs and cats through pharmacokinetic studies and clinical experience. Others are extrapolated from human medicine, where the mechanisms are shared but the clinical consequences may differ by species, dose, and disease state. Where the veterinary literature is thin, this article identifies the gap explicitly instead of asserting certainty. The reader should consult current formulary references and product labels for dosing specifics, as published ranges vary by indication and species.

At a Glance

Pharmacologic Foundations of Antihypertensive Interactions

Antihypertensive drugs do not act in isolation. They modulate the renin-angiotensin-aldosterone system (RAAS), sympathetic outflow, vascular smooth muscle calcium flux, or renal sodium handling. When a second drug engages the same pathway, the interaction is often additive or synergistic. When it engages a counter-regulatory pathway, the interaction may be antagonistic. Understanding which pathway a drug touches predicts the direction of the interaction before clinical signs appear.

ACE inhibitors reduce angiotensin II formation and aldosterone secretion. This lowers blood pressure but also reduces efferent arteriolar tone in the kidney, which decreases glomerular filtration pressure. Any drug that further reduces renal perfusion, such as an NSAID or a diuretic, compounds this effect. The combination of ACE inhibition and cyclooxygenase inhibition is the most clinically significant drug interaction in veterinary antihypertensive therapy because both drug classes are prescribed frequently in the same patient populations, particularly older dogs with chronic kidney disease and osteoarthritis.

Calcium channel blockers, specifically amlodipine, act on vascular smooth muscle L-type channels. They are first-line for feline hypertension because they are potent, well tolerated, and do not depend on renal activation for their effect. Their interaction profile is dominated by additive vasodilation with anesthetics and by pharmacokinetic interactions with drugs that inhibit or induce cytochrome P450 enzymes. Diltiazem and verapamil, less commonly used for systemic hypertension in small animals, additionally slow atrioventricular conduction and interact additively with beta-blockers.

Beta-blockers antagonize catecholamine effects at beta-1 and beta-2 receptors. The interaction of greatest concern is with epinephrine or other alpha-beta agonists: beta-blockade leaves alpha-mediated vasoconstriction unopposed, producing paradoxic hypertension. This interaction is relevant in anesthetic emergencies and in patients receiving local anesthetics with epinephrine.

The Renin-Angiotensin Axis and Renal Interactions

The ACE inhibitor-NSAID interaction deserves detailed attention because it is common, preventable, and potentially injurious. NSAIDs inhibit prostaglandin synthesis, and renal prostaglandins maintain afferent arteriolar dilation in the volume-replete kidney. When afferent dilation is lost and efferent dilation is simultaneously induced by ACE inhibition, glomerular filtration pressure falls. The result is an acute rise in serum creatinine, often within days of starting the combination. Hyperkalemia follows because aldosterone secretion is suppressed by the ACE inhibitor and further reduced by prostaglandin inhibition of renin release.

Clinical decision-making requires risk stratification. A normotensive dog with normal renal function and stable osteoarthritis may tolerate the combination with monitoring. A dog with pre-existing chronic kidney disease, dehydration, or congestive heart failure receiving furosemide is at substantially higher risk. In that patient, the clinician should either avoid the combination or use a COX-2 selective NSAID with caution, recognizing that selectivity does not eliminate renal risk. Serum creatinine and potassium should be rechecked within 7 days of starting the combination and after any dose change.

Corticosteroids interact with antihypertensive therapy through sodium and water retention, which opposes the natriuretic effect of ACE inhibitors and diuretics. The result is often apparent antihypertensive failure: blood pressure rises or does not respond to dose escalation. The interaction is dose dependent and more pronounced with mineralocorticoid-active steroids such as fludrocortisone. In a hypertensive patient requiring corticosteroids, the clinician should anticipate a blood pressure increase and may need to adjust antihypertensive doses accordingly. Blood pressure should be reassessed within 2 weeks of starting or stopping corticosteroid therapy.

Interactions with Immunosuppressive and Antiseizure Medications

Antihypertensive drugs and immunosuppressants are co-prescribed in veterinary patients with immune-mediated disease and in research settings. The interaction between ACE inhibitors and mammalian target of rapamycin (mTOR) inhibitors such as sirolimus has been examined in human renal transplant recipients, where the combination produced more effective regression of left ventricular hypertrophy than either agent alone, but also raised concerns about additive nephrotoxicity. The relevance to veterinary patients is indirect but instructive: when an ACE inhibitor is added to an mTOR inhibitor, renal function and blood pressure should be monitored together, not as independent parameters. The veterinary literature does not yet provide species-specific dosing guidance for this combination.

Antiseizure medications interact with antihypertensive drugs primarily through hepatic enzyme induction. Phenobarbital induces cytochrome P450 enzymes and can reduce plasma concentrations of calcium channel blockers, particularly those metabolized by CYP3A4. Felodipine and amlodipine are affected to varying degrees. In a dog receiving phenobarbital and amlodipine, the antihypertensive effect may be blunted, and dose escalation may be required. Therapeutic drug monitoring for amlodipine is not routinely available, so the clinician should rely on blood pressure measurement to guide dosing. Conversely, some antihypertensive drugs have antiseizure or proconvulsant properties that may matter in epileptic patients. Propranolol and several calcium channel blockers have shown antiseizure effects in experimental models, while clonidine and high-dose propranolol have been associated with proconvulsant effects. These observations come from human and experimental literature and should be interpreted cautiously in veterinary patients, but they argue for careful blood pressure and seizure frequency monitoring when these drugs are combined.

Interactions with NSAIDs, Corticosteroids, and Other Common Adjunctive Drugs

NSAIDs and Antihypertensive Efficacy

Non-steroidal anti-inflammatory drugs oppose the action of most antihypertensive agents through multiple mechanisms. Inhibition of cyclooxygenase reduces renal prostaglandin synthesis, which diminishes afferent arteriolar vasodilation and promotes sodium and water retention. The clinical consequence is a measurable attenuation of antihypertensive effect, most pronounced with ACE inhibitors and angiotensin receptor blockers, where prostaglandin-dependent renal hemodynamics contribute substantially to their mechanism of action.

In dogs receiving chronic NSAID therapy, the blood pressure response to an ACE inhibitor may be blunted by 5 to 10 mmHg, an effect that can be clinically significant in a patient already at the upper limit of the target range. The interaction is dose-dependent and more prominent with non-selective NSAIDs than with COX-2 preferential agents, although no NSAID is entirely free of this effect. Cats appear similarly affected, and the combination of an NSAID with an ACE inhibitor in a patient with pre-existing renal disease carries the additional risk of acute kidney injury from combined reduction in glomerular perfusion pressure.

The decision framework should include the following steps. First, establish whether the NSAID is essential or can be withdrawn, reduced, or replaced with an alternative analgesic strategy. Second, if the NSAID must continue, recheck blood pressure within 7 to 14 days of any dose change in either drug. Third, monitor serum creatinine and potassium, particularly in the first month of combined therapy. Fourth, recognize that the interaction is reversible, blood pressure may fall when the NSAID is discontinued, and the antihypertensive dose may then require downward adjustment.

Corticosteroids and Blood Pressure Elevation

Glucocorticoids and mineralocorticoids raise blood pressure through sodium retention, expanded plasma volume, and increased vascular reactivity to endogenous catecholamines. The effect is dose-dependent and occurs with oral, injectable, and topical formulations that achieve systemic absorption. In a patient already receiving an antihypertensive agent, the addition of a corticosteroid can partially or completely negate the therapeutic response.

The interaction is particularly relevant in dogs with immune-mediated disease, where prednisone is often initiated concurrently with or shortly after antihypertensive therapy. A dog whose blood pressure was well controlled on amlodipine may show a 10 to 20 mmHg increase within days of starting prednisone at immunosuppressive doses. The response is less predictable in cats, but the same principle applies.

Management requires anticipation instead of reaction. When corticosteroids are initiated in a hypertensive patient, schedule a blood pressure recheck within 7 days. If the blood pressure rises above the target range, the first response is to confirm the elevation with repeat measurement and then consider whether the corticosteroid dose can be tapered. If it cannot, the antihypertensive dose may need upward titration, with the understanding that it will need to be reduced again when the corticosteroid is withdrawn. The reverse sequence also matters: a patient whose blood pressure has been stable on a given antihypertensive dose may become hypotensive when corticosteroids are tapered or discontinued.

Antihypertensives and Anesthetic Drug Interactions

The perioperative period concentrates the risk of antihypertensive drug interactions because anesthetic agents, analgesics, and the physiologic stress of surgery all affect blood pressure. The prevailing recommendation in human perioperative medicine is to continue antihypertensive medications through surgery instead of withdraw them, because uncontrolled preoperative hypertension is a greater risk factor for intraoperative instability than the medications themselves. This principle transfers to veterinary patients, with the caveat that the anesthetic protocol must be adjusted accordingly perioperative medication management in elective surgery.

ACE inhibitors and angiotensin receptor blockers deserve particular attention. These agents reduce the compensatory renin-angiotensin response to hypovolemia and vasodilation, which can produce profound hypotension during anesthesia, particularly when combined with inhalant anesthetics that themselves cause dose-dependent vasodilation. The risk is highest in patients with concurrent dehydration, blood loss, or cardiac disease. Some anesthesiologists recommend withholding the morning dose of an ACE inhibitor before elective procedures, while others continue it and manage hypotension with vasopressors and fluid therapy. The correct choice depends on the indication for the ACE inhibitor, the procedure, and the anticipated fluid shifts. For a dog receiving an ACE inhibitor for proteinuric nephropathy undergoing a dental cleaning, withholding the dose is low-risk. For a dog with congestive heart failure undergoing the same procedure, continuation is safer.

Beta-blockers should generally be continued through the perioperative period. Abrupt withdrawal can precipitate reflex tachycardia, hypertension, and myocardial ischemia. The interaction with anesthetic agents is additive bradycardia and hypotension, which is managed by reducing inhalant concentration and using anticholinergics judiciously. Amlodipine and other dihydropyridine calcium channel blockers have a long duration of action and are typically continued, with the understanding that their vasodilatory effect will sum with that of the anesthetics.

The monitoring protocol for the hypertensive patient under anesthesia should include blood pressure measurement at intervals no longer than 5 minutes during the stable phase, with more frequent measurement during induction and recovery. Hypotension, defined as a mean arterial pressure below 60 mmHg, should be treated first by reducing anesthetic depth and second by fluid therapy. Vasopressor support is indicated when hypotension persists despite these measures.

Interactions with Sympathomimetics and Vasopressors

Patients receiving antihypertensive therapy may be exposed to sympathomimetic agents in several contexts: as vasopressors during anesthesia, as decongestants, or as inadvertent components of compounded products. The interaction depends on the class of antihypertensive and the specific sympathomimetic. A patient on a non-selective beta-blocker who receives epinephrine may experience unopposed alpha-adrenergic vasoconstriction, producing severe hypertension. A patient on an ACE inhibitor who receives a vasopressor may show an exaggerated pressor response because the normal counter-regulatory vasodilation is impaired.

The practical rule is to use the lowest effective dose of any vasopressor in a patient receiving antihypertensive therapy and to monitor blood pressure continuously during administration. The response to vasopressors should be titrated to effect instead of given as a fixed bolus.

Monitoring Parameters and Documentation

The following table summarizes the key interactions, their mechanisms, and the monitoring parameters that detect them.

Documentation of these interactions should include the baseline blood pressure, the date of any drug addition or dose change, the follow-up blood pressure measurement, and the clinical decision made in response. The medical record should state explicitly when a drug interaction is suspected and what monitoring plan has been instituted. This documentation serves both clinical continuity and medicolegal protection.

Species differences matter in the application of these principles. Cats are more sensitive to the hypertensive effects of corticosteroids than dogs and may require more frequent monitoring. Dogs with chronic kidney disease are at higher risk of the renal effects of NSAID-antihypertensive combinations. The equipment available also changes the approach: oscillometric blood pressure devices may underestimate or overestimate pressure in small patients, and Doppler methods, while reliable for systolic pressure, do not provide diastolic or mean values. The monitoring plan should be tailored to the patient, the drugs involved, and the practice setting.

Recognized Complications and Early Detection

The principal failure modes in antihypertensive therapy are hypotension, acute kidney injury, hyperkalemia, and loss of efficacy from drug interactions. Each has a characteriztic temporal profile and a discriminating diagnostic maneuve.

Hypotension most often emerges within 2 to 6 hours of dose initiation or escalation, particularly when an angiotensin-converting enzyme inhibitor is added to a patient already receiving a diuretic or when amlodipine is combined with a beta-blocker. Early detection relies on serial blood pressure measurement instead of clinical gestalt, because mucous membrane color and pulse quality remain normal until mean arterial pressure falls below approximately 60 mm Hg. The discriminating check is a post-dose blood pressure reading taken at the expected peak effect, compared with a pre-dose baseline. In cats receiving amlodipine, the peak effect occurs roughly 3 to 6 hours after administration, and a single reading below 100 mm Hg systolic warrants dose reduction even in the absence of clinical signs.

Acute kidney injury from renin-angiotensin system blockade is detected by monitoring serum creatinine and urine output within 3 to 7 days of starting therapy or after any dose increase. A rise in creatinine exceeding 30 percent above baseline, or an absolute increase of 0.5 mg/dL, should prompt evaluation of volume status and concurrent medications. The interaction with NSAIDs is the most common preventable cause, because prostaglandin-dependent afferent arteriolar vasodilation is already compromised by ACE inhibition. The discriminating check is a fractional excretion of sodium or a urine specific gravity measurement to distinguish prerenal azotaemia from intrinsic injury, followed by temporary discontinuation of the NSAID instead of the ACE inhibitor.

Hyperkalemia develops insidiously and is frequently asymptomatic until serum potassium exceeds 6.0 mmol/L. The combination of an ACE inhibitor with a potassium-sparing diuretic, an aldosterone antagonist, or an NSAID is the classic precipitant. Detection requires a biochemistry panel, not clinical examination, and should be performed 7 to 10 days after adding any second agent that affects potassium handling. The discriminating check is a paired potassium and creatinine measurement, because hyperkalemia with normal renal function suggests a drug interaction, whereas hyperkalemia with azotaemia suggests structural nephron loss.

Common Errors and Corrective Actions

Less experienced clinicians frequently attribute a rising creatinine to progression of renal disease when the actual cause is an interaction between an ACE inhibitor and an NSAID. The corrective action is a structured medication reconciliation at every visit, with explicit questioning about over-the-counter and owner-administered anti-inflammatory drugs. Cats are particularly vulnerable because owners may administer human ibuprofen or naproxen without veterinary knowledge, and the resulting interaction can produce acute renal failure within days.

A second recurring error is discontinuing antihypertensive therapy before anesthesia without a plan for blood pressure support. The perioperative literature in human plastic surgery emphasizes that most antihypertensive medications should be continued through surgery, with the exception of those that increase bleeding risk, and that abrupt withdrawal can cause rebound hypertension or tachycardia. The same principle applies in veterinary patients. The corrective action is to continue ACE inhibitors and calcium channel blockers through the perioperative period, to measure blood pressure immediately after induction, and to have a vasopressor available instead of relying on the interaction between anesthetic agents and the antihypertensive drug to resolve itself.

A third error is the assumption that all beta-blockers behave identically. Propranolol has antiseizure properties at therapeutic doses, whereas other beta-blockers do not, and high-dose propranolol has been associated with proconvulsant effects in experimental models. The corrective action is to select a beta-blocker based on the specific comorbidity, and to avoid switching agents without considering the seizure threshold implications in epileptic patients.

Limitations of Current Evidence

The veterinary evidence base for antihypertensive drug interactions is largely extrapolated from human medicine and from experimental models. Controlled interaction studies in dogs and cats are sparse, and most clinical guidance derives from case series, pharmacokinetic modeling, and expert consensus. The interaction between ACE inhibitors and immunosuppressive agents, for example, has been studied in human renal transplant recipients, where the combination of an ACE inhibitor and sirolimus has been evaluated for regression of left ventricular hypertrophy. Whether the same interaction profile applies to dogs receiving cyclosporine or mycophenolate is unknown, and extrapolation should be cautious.

Expert opinion differs on the management of the NSAID-ACE inhibitor interaction in patients with chronic kidney disease. Some authorities recommend complete avoidance of NSAIDs in any patient receiving an ACE inhibitor, while others permit short courses at the lowest effective dose with close monitoring. The evidence does not resolve this disagreement, and the clinician must weigh the analgesic benefit against the renal risk on a case-by-case basis. Similarly, the perioperative management of amlodipine in cats remains contested, with some anesthetists recommending continuation and others preferring to hold the dose on the morning of surgery to reduce the risk of anesthetic-induced hypotension.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when blood pressure remains uncontrolled despite sequential addition of two antihypertensive agents from different classes, when suspected hyperkalemia or acute kidney injury does not resolve within 72 hours of removing the offending drug, or when a hypertensive emergency requires intravenous therapy that the primary clinician cannot provide. A veterinary cardiologist or internal medicine specialist should also be consulted before combining three or more antihypertensive agents, because the interaction surface expands geometrically and the risk of hypotension increases disproportionately.

Laboratory involvement is indicated for therapeutic drug monitoring of antiseizure medications that interact with antihypertensive agents, particularly when enzyme-inducing drugs alter the metabolism of calcium channel blockers. A clinical pathologist can assist in interpreting serial creatinine and potassium trends and in distinguishing drug-induced injury from progression of underlying disease.

Regulatory reporting is required when an adverse drug event involves a product approved by the FDA Center for Veterinary Medicine, and the agency maintains an adverse event reporting system for animal drugs. Reporting is also appropriate when a suspected interaction produces a serious outcome, such as hospitalization, permanent disability, or death, even if the causal relationship is uncertain. The report should include the suspected drugs, the time course, concurrent medications, and the outcome, and should be filed even when the interaction is already described in the product label.

Frequently Asked Questions

How should I adjust antihypertensive therapy when a patient needs long-term NSAID treatment for osteoarthritis?

The expected reduction in antihypertensive efficacy should be discussed with the owner before starting NSAID therapy. ACE inhibitors and angiotensin receptor blockers lose effectiveness through sodium retention and reduced renal prostaglandin synthesis. Recheck blood pressure 7 to 14 days after initiating the NSAID and again after any dose change. If systolic pressure rises above the target for that patient, consider adding amlodipine instead of escalating the ACE inhibitor dose, since the interaction is mechanism-based and dose escalation often yields little benefit. Gastroprotectant coadministration does not reverse the blood pressure effect. Document the interaction in the record and schedule a follow-up pressure measurement within one month.

What monitoring is practical when a hypertensive cat develops chronic kidney disease and needs both amlodipine and an ACE inhibitor?

Combine the drugs at the lowest effective doses and stage the introduction, starting one agent and confirming tolerance before adding the second. Measure blood pressure, creatinine, and potassium 7 to 10 days after each addition or dose change. A creatinine rise of less than 30 percent from baseline is generally acceptable, while a larger increase warrants dose reduction or discontinuation of the ACE inhibitor. The MSD Veterinary Manual provides species-specific guidance on monitoring intervals and target blood pressure ranges. If the cat cannot return for frequent visits, ask the owner to monitor appetite and activity and prioritize a combined visit for pressure measurement and biochemistry within two weeks of any drug change.

Can I continue antihypertensive medication on the morning of anesthesia, or should I withhold it?

Most veterinary anesthesiologists recommend continuing ACE inhibitors and amlodipine through the morning of anesthesia to maintain hemodynamic stability during induction, provided the patient is volume replete. Beta-blockers should generally be continued to avoid reflex tachycardia and hypertensive crisis from abrupt withdrawal. The interaction between antihypertensives and anesthetic agents is primarily additive vasodilation and blunted compensatory responses, so anticipate a higher requirement for intravenous fluids and a lower induction dose of propofol or other agents. Perioperative medication decisions in human surgery increasingly favor continuing cardiovascular drugs, and similar reasoning applies in veterinary patients, as reviewed in perioperative medication management literature. Hypotension during anesthesia is managed with vasopressors and fluid boluses instead of by withholding the maintenance antihypertensive.

What should I do if I cannot measure blood pressure reliably in a fractious dog that is on multiple interacting drugs?

A single unreliable reading should not drive dose changes. Use a Doppler device in a quiet room with the dog unrestrained, and take three to five readings, discarding the first. If the dog remains too agitated, consider a short course of trazodone or gabapentin for the visit, since these do not meaningfully interact with most antihypertensives. When pressure cannot be obtained, base decisions on indirect markers: serial creatinine, urine protein-to-creatinine ratio, fundic examination for hypertensive retinopathy, and owner-reported signs such as lethargy or blindness. Document the limitation explicitly in the record and schedule a recheck with pre-visit anxiolytic medication. The AVMA practice resources offer guidance on adapting examination protocols to difficult patients.

How do I explain the NSAID interaction to an owner who insists their dog needs pain relief?

Frame the conversation around balancing two treatment goals instead of choosing one. Explain that the blood pressure medication and the pain reliever work against each other in the kidney, so the dog may need a higher dose of one drug, an additional blood pressure drug, or a different pain management plan. Emphasize that the interaction is manageable with monitoring, not a reason to withhold pain relief. Offer concrete options: a different NSAID class, a non-NSAID analgesic such as gabapentin or amantadine, or a temporary increase in monitoring frequency. Written instructions with the recheck date and warning signs such as weakness or collapse help owners follow through. The FDA Center for Veterinary Medicine maintains adverse event reporting resources if the owner reports an unexpected reaction.

Does the interaction between antihypertensives and immunosuppressive drugs matter in veterinary patients beyond transplant medicine?

The interaction is relevant in any patient receiving cyclosporine, including dogs with atopic dermatitis or immune-mediated disease. Cyclosporine can raise blood pressure directly and may reduce the efficacy of ACE inhibitors through renal vasoconstriction. Conversely, some antihypertensive classes may alter calcineurin inhibitor metabolism, though the clinical significance in dogs and cats is less well defined than in human transplant recipients. In human renal transplant patients, ACE inhibitor therapy has been associated with regression of left ventricular hypertrophy, and interactions between antihypertensive and immunosuppressive agents are an active area of study, as described in a review of left ventricular hypertrophy after transplantation. In veterinary patients, monitor blood pressure weekly for the first month of combined therapy and adjust antihypertensive dosing based on trends instead of single readings.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.. 2009.
• Decoding cytokine interactions for psoriasis therapy through computational repurposing of antihypertensive drugs.. 2026.
• Drug treatments in patients with cardiac diseases and epilepsy.. 2020.
• Perioperative Medication Management in Elective Plastic Surgery Procedures.. 2023.
• A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy.. 2023.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Drug Interactions with Anticonvulsant Medications in Veterinary Patients: Phenobarbital, Potassium Bromide, and Levetiracetam
• Drug Interactions with Cardiovascular Medications in Veterinary Patients: Beta-Blockers, ACE Inhibitors, and More
• Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients
• Drug Interactions with Antidiabetic Medications in Dogs and Cats
• Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.